As noted by experts at the University of Connecticut, GLP-1 peptide molecules are too large to effectively penetrate the skin barrier, making transdermal delivery of actual GLP-1 medications currently impossible with existing technology
These findings suggest that it is possible to increase GLP-1 secretion and manage T2DM and its complications by restoring and improving the gut microbiota [158]
hypertension, type 2 DM, dyslipidemia) A meta-analysis of 22 trials involving over 17,000 patients determined that 50.2% and 17.5% of patients treated with GLP-1RAs (exenatide, semaglutide & liraglutide) experienced a weight loss of 5% and 10% compared to placebo, and that patients without type 2 diabetes achieved a significantly greater weight loss compared to those with diabetes (Vosoughi et al, 2022)
( / and ApoE / mice on a Western diet (WD) were given daily injections of liraglutide or semaglutide or vehicle control for 12 to 17 weeks (12 to 14 weeks in ApoE / mice and 17 weeks in LDLr / mice)
Medicare Part D cannot cover drugs used strictly for weight loss, though a GLP-1 may be covered for a qualifying condition like diabetes